<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-8D54MKDW</identifier><date>2000</date><creator>Polanec, Janja</creator><relation>documents/doc/8/URN_NBN_SI_doc-8D54MKDW_001.pdf</relation><relation>documents/doc/8/URN_NBN_SI_doc-8D54MKDW_001.txt</relation><format format_type="issue">2</format><format format_type="volume">4</format><format format_type="type">article</format><format format_type="extent">str. 75-76</format><identifier identifier_type="COBISSID">12577497</identifier><identifier identifier_type="ISSN">1408-1741</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-8D54MKDW</identifier><language>slv</language><publisher>Onkološki inštitut Ljubljana</publisher><source>Onkologija (Ljubljana)</source><rights>BY</rights><subject language_type_id="eng">Drug therapy</subject><subject language_type_id="slv">gensko zdravljenje</subject><subject language_type_id="eng">Hematologic neoplasms</subject><subject language_type_id="eng">Oligonucleotides, antisense</subject><subject language_type_id="slv">onkologija</subject><subject language_type_id="slv">rak (medicina)</subject><subject language_type_id="eng">Therapeutic use</subject><subject language_type_id="eng">therapy</subject><subject language_type_id="slv">zdravljenje</subject><title>Zdravljenje s protismernimi oligonukleotidi</title></Record>